Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference

医学 慢性肝炎 临床试验 临床终点 乙型肝炎 乙型肝炎病毒 病毒学 内科学 病毒
作者
Markus Cornberg,Anna Suk-Fong Lok,Norah A. Terrault,Fabien Zoulim
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:71 (3): 1070-1092 被引量:124
标识
DOI:10.1002/hep.31030
摘要

Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to 'cure' HBV. Agreement among the conference participants was reached on some key points. 'Functional' but not sterilizing cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable HBV DNA 6 months post-treatment. The primary endpoint of phase 3 trials should be functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of response in these trials. Sustained virologic suppression (undetectable serum HBV DNA) without HBsAg loss, 6 months after discontinuation of treatment would be an intermediate goal. Demonstrated validity in predicting sustained HBsAg loss was considered the most appropriate criterion for the approval of new HBV assays to determine efficacy endpoints. Clinical trials aimed at HBV functional cure should initially focus on patients with HBeAg-positive and HBeAg-negative chronic hepatitis, treatment-naïve or virally suppressed on nucleos(t)ide analogues. A hepatitis flare associated with increase in bilirubin or INR should prompt temporary or permanent cessation of investigational treatment. New treatments must be as safe as existing nucleos(t)ide analogues. The primary endpoint for phase 3 trials for hepatitis D virus (HDV) co-infection should be undetectable serum HDV RNA 6 months after stopping treatment. On treatment HDV RNA suppression associated with normalization of ALT is considered an intermediate goal. CONCLUSION: For HBV 'functional cure', sustained HBsAg loss with undetectable HBV DNA after completion of treatment is the primary goal and sustained undetectable HBV DNA without HBsAg loss after stopping treatment an intermediate goal.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
科研通AI6.3的应助被wjp采纳,获得10
刚刚
1秒前
wztao完成签到,获得积分10
1秒前
司徒南瓜饼完成签到,获得积分10
2秒前
梅溜溜完成签到,获得积分10
2秒前
小蘑菇的应助被正直未来采纳,获得10
3秒前
Miao发布了新的文献求助10
3秒前
搜集达人的应助被CWJ采纳,获得20
3秒前
香蕉觅云的应助被CWJ采纳,获得10
3秒前
molihuakai的应助被CWJ采纳,获得10
4秒前
隐形曼青的应助被CWJ采纳,获得10
4秒前
研友_VZG7GZ的应助被CWJ采纳,获得10
4秒前
4秒前
秋风的应助被CWJ采纳,获得20
4秒前
慕青的应助被wztao采纳,获得10
4秒前
4秒前
安静的怜容完成签到 ,获得积分10
4秒前
5秒前
果味儿丫头完成签到,获得积分10
5秒前
四夕完成签到 ,获得积分10
6秒前
胡帅完成签到 ,获得积分10
6秒前
活力幻儿关注了科研通微信公众号
6秒前
潘骑杰发布了新的文献求助10
6秒前
JamesPei的应助被sxnyyy采纳,获得10
7秒前
小刘同学完成签到,获得积分10
7秒前
思川完成签到,获得积分10
7秒前
李麟发布了新的文献求助10
8秒前
8秒前
伶俐的雁梅完成签到 ,获得积分10
8秒前
李健的应助被vbmc采纳,获得10
9秒前
可期发布了新的文献求助10
10秒前
777发布了新的文献求助10
10秒前
orixero的应助被lzx采纳,获得10
10秒前
所所的应助被糖醋鱼采纳,获得30
11秒前
13秒前
无花果的应助被地火丢采纳,获得10
13秒前
zzzz完成签到 ,获得积分10
14秒前
14秒前
123发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371